STOCK TITAN

Oramed grants Miriam Kidron 357,000 restricted shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. granted Chief Scientific Officer and director Miriam Kidron two restricted stock awards on November 12, 2026: 357,000 shares and 242,000 shares.

The 357,000-share award vests only if fiscal 2026 return on equity exceeds 18%; 50% vests when audited fiscal 2026 financial statements are published and 50% six months later, subject to continued service. Otherwise, all shares are forfeited. The 242,000-share award represents annual awards for fiscal 2027 and 2028, with 121,000 shares vesting in 12 substantially equal quarterly installments beginning January 1, 2027, and another 121,000 shares on the same schedule beginning January 1, 2028, subject to continued service. No annual award will be granted for fiscal 2028.

Insider Kidron Miriam
Role Chief Scientific Officer
Type Security Shares Price Value
Grant/Award Common Stock F1 357,000 -- --
Grant/Award Common Stock F2 242,000 -- --
Holdings After Transaction: Common Stock — 2,149,554 shares (Direct)
Holdings Before and After: Common Stock, 1,550,554 to 2,149,554 shares (Direct)
Footnotes (2)
  1. F1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 357,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
  2. F2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 242,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
Restricted stock award 357,000 shares Granted November 12, 2026; subject to a fiscal 2026 return-on-equity condition
Return on equity threshold 18% Fiscal year 2026 condition for the 357,000-share award
Initial vesting tranche 50% Vests when audited fiscal 2026 financial statements are published if the return-on-equity condition is met
Second vesting tranche 50% Vests six months after publication of audited fiscal 2026 financial statements if the condition is met
Restricted stock award 242,000 shares Granted November 12, 2026; represents annual awards for fiscal years 2027 and 2028
Fiscal 2027 award installments 121,000 shares Vest in 12 substantially equal quarterly installments beginning January 1, 2027, subject to continued service
Fiscal 2028 award installments 121,000 shares Vest in 12 substantially equal quarterly installments beginning January 1, 2028, subject to continued service
restricted stock award financial
"a restricted stock award of 357,000 shares"
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
return on equity financial
"return on equity for fiscal year 2026 exceeds 18%"
Return on equity shows how effectively a company uses its shareholders' money to generate profit. It is calculated by dividing the company's net profit by its shareholders' equity, indicating how much profit is earned for each dollar invested by owners. Higher return on equity suggests the company is good at turning investments into earnings, which can be an important factor for investors assessing its profitability and efficiency.
Amended and Restated 2019 Stock Incentive Plan financial
"under the issuer's Amended and Restated 2019 Stock Incentive Plan"
substantially equal quarterly installments financial
"in twelve substantially equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock awards did ORMP grant Miriam Kidron?

On November 12, 2026, Oramed Pharmaceuticals granted Chief Scientific Officer and director Miriam Kidron restricted stock awards of 357,000 shares and 242,000 shares. Each award is subject to its stated vesting terms.

What are the vesting conditions for Miriam Kidron’s 357,000-share ORMP award?

The award vests only if Oramed Pharmaceuticals’ return on equity for fiscal year 2026 exceeds 18%. If that condition is met, 50% vests when audited fiscal 2026 financial statements are published and 50% six months later, subject to continued service. If the condition is not met, all shares are forfeited.

How does Miriam Kidron’s 242,000-share ORMP award vest?

The award represents annual awards for fiscal years 2027 and 2028. Of the shares, 121,000 vest in 12 substantially equal quarterly installments beginning January 1, 2027, and 121,000 vest in 12 substantially equal quarterly installments beginning January 1, 2028; both schedules are subject to continued service. No annual award will be granted for fiscal 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kidron Miriam

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026A357,000A(1)1,907,554D
Common Stock11/12/2026A242,000A(2)2,149,554D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 357,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 242,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
/s/ Miriam Kidron11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading